Breast Cancer Clinical Trial

Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer

Summary

The study will determine the sensitivity, specificity, negative predictive value and positive predictive value of the OSNA Breast Cancer System by comparing its performance to permanent section Hematoxylin and Eosin (H&E) and IHC staining.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Male or Female patients, over the age of 18, diagnosed pre-surgically with T1 or T2 breast cancer and scheduled for surgery including sentinel node dissection.
Patients who have read and understand the informed consent form and are capable and willing to provide written informed consent.

Exclusion Criteria:

Patients diagnosed pre-surgically with large or locally advanced (T3 and T4) breast cancers.
Patients diagnosed with inflammatory breast cancer.
Patients diagnosed with ductal carcinoma in situ (DCIS) when breast conserving is to be done.
Patients who are pregnant, as confirmed by a patient/treating physician interview.
Patients with suspicious palpable axillary lymph nodes.
Patients currently being treated for or previously diagnosed with, another type of carcinoma.
Patients who have undergone prior non-oncologic breast surgery or axillary surgery.
Patients who have received pre-operative systemic therapy.
Patients who are incapable of providing written informed consent.
Patients who have been judged to be inappropriate by a medical care provider (i.e. surgeon, oncologist, pathologists, etc.).

Study is for people with:

Breast Cancer

Estimated Enrollment:

496

Study ID:

NCT01136369

Recruitment Status:

Completed

Sponsor:

Sysmex America, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 11 Locations for this study

See Locations Near You

John Wayne Cancer Institute
Santa Monica California, 90404, United States
WellStar Health Systems
Marietta Georgia, 30062, United States
Washington University Medical School
Saint Louis Missouri, 63110, United States
Beth Israel Medical Center
New York New York, 10003, United States
Central Carolina Surgery, PA
Greensboro North Carolina, 27401, United States
Wake Forest University Health Sciences
Winston-Salem North Carolina, 27157, United States
Breast Care Specialist, Inc.
Westerville Ohio, 43081, United States
Breast Care Specialist, PC
Allentown Pennsylvania, 18104, United States
Nashville Breast Center, PC
Nashville Tennessee, 37203, United States
Dallas Surgical Group
Dallas Texas, 75230, United States
University of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

496

Study ID:

NCT01136369

Recruitment Status:

Completed

Sponsor:


Sysmex America, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.